Objective: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …

Objectives To evaluate the efficacy and safety of rituximab in patients with primary Sjögren's
syndrome (pSS). Methods The AutoImmune and Rituximab registry has included 86 patients …

CONCLUSIONS Rituximab appeared to be effective for at least 6–9 months in patients with
pSS with active disease, improving subjective and objective symptoms. Development of …

Objective To evaluate rituximab (RTX) in primary Sjögren's syndrome (pSS) with peripheral
nervous system (PNS) involvement. Methods Patients with pSS and PNS involvement who …

Methods. Fifteen patients with primary SS were included in this phase II trial. Inclusion
criteria for the early primary SS group were B cell hyperactivity (IgG> 15 gm/liter), presence …

Objective To study the safety and clinical efficacy of rituximab therapy for primary Sjögren's
syndrome, as well as to investigate its mechanisms. Methods Patients with primary Sjögren's …

Objective. To study the efficacy and safety of B cell depletion with rituximab, a chimeric
murine/human anti-CD20 monoclonal antibody, in patients with primary Sjögren's syndrome …

Background: Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by
ocular and oral dryness or systemic manifestations. Objective: To evaluate efficacy and …

Abstract Introduction Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting
exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular …

Abstract Background Primary Sjögren's Syndrome (PSS) mainly affects women (9: 1 female:
male ratio) and is one of the commonest autoimmune diseases with a prevalence of 0.1 …